Published in N Engl J Med on August 01, 1991
Studies of Left Ventricular Dysfunction (SOLVD) | NCT00000516
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Open access echocardiography in management of heart failure in the community. BMJ (1995) 7.83
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA (2011) 4.09
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation (2009) 3.55
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ (1998) 3.14
Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol (2009) 2.93
Knowledge, patterns of care, and outcomes of care for generalists and specialists. J Gen Intern Med (1999) 2.76
Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. JAMA (2010) 2.73
Drug therapy in chronic heart failure. Postgrad Med J (2003) 2.73
Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57
Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health (1997) 2.51
A story of maladies, misconceptions and mishaps: effective management of heart failure. Soc Sci Med (2004) 2.25
Heart failure: Part I. First hospitalization and post-hospital care. West J Med (1999) 2.10
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. Heart (1997) 2.04
Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail (2011) 2.01
Intravenous fluids in acute decompensated heart failure. JACC Heart Fail (2015) 2.01
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ (2002) 1.99
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol (2010) 1.93
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol (2013) 1.91
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89
Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med (2008) 1.88
Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest (2006) 1.81
Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol (2010) 1.77
Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. BMJ (2000) 1.68
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Noninvasive imaging of angiotensin receptors after myocardial infarction. JACC Cardiovasc Imaging (2008) 1.67
ACE inhibitors--a cornerstone of the treatment of heart failure. N Engl J Med (1991) 1.67
Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure. Circ Arrhythm Electrophysiol (2011) 1.56
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J (2016) 1.54
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
The "number needed to treat" turns 20--and continues to be used and misused. CMAJ (2008) 1.52
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ (2008) 1.51
Beneficial haemodynamic effects of insulin in chronic heart failure. Heart (2001) 1.50
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care? Health Serv Res (2007) 1.49
ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians? Postgrad Med J (1999) 1.49
Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev (2011) 1.49
Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail (2015) 1.48
Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med (1997) 1.48
Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol (1997) 1.48
The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm (2014) 1.47
The need for palliative care in the management of heart failure. Heart (2002) 1.44
The impact of Medicare Part D on hospitalization rates. Health Serv Res (2011) 1.43
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol (2011) 1.38
New developments in the treatment of cardiac failure. Arch Dis Child (1999) 1.38
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer (2009) 1.38
Management of acute decompensated heart failure. CMAJ (2007) 1.33
Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail (2008) 1.32
Estimated pseudopartial-likelihood method for correlated failure time data with auxiliary covariates. Biometrics (2009) 1.29
Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. Br J Clin Pharmacol (2001) 1.27
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.27
The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev (2004) 1.27
Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart (2003) 1.26
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail (2015) 1.25
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Prognostic value of 6-minute walk test in stable outpatients with heart failure. Tex Heart Inst J (2007) 1.23
The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract (2006) 1.22
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med (2012) 1.22
Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ (2002) 1.22
Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations. Br J Gen Pract (2000) 1.21
Open-access echocardiography to general practitioners for suspected heart failure. Br J Gen Pract (1996) 1.20
Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J (2010) 1.20
Diabetic cardiomyopathy. Clin Sci (Lond) (2009) 1.18
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J (2001) 1.18
The management of congestive heart failure. Postgrad Med J (1997) 1.16
The Heart Failure Adherence and Retention Trial (HART): design and rationale. Am Heart J (2008) 1.16
β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol (2012) 1.15
Cardiomyopathy, familial dilated. Orphanet J Rare Dis (2006) 1.14
Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol (2012) 1.14
NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart (2003) 1.13
Drug treatment in heart failure. BMJ (2000) 1.13
Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther (2005) 1.13
Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993-2010: findings from a university referral center. Circ Heart Fail (2013) 1.12
Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol (2003) 1.12
Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res (2003) 1.10
Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2012) 1.09
Recent advances involving the renin-angiotensin system. Exp Cell Res (2012) 1.09
Morphological aspects of apoptosis in heart diseases. J Cell Mol Med (2006) 1.09
Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death. Sci Transl Med (2013) 1.08
Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction. J Gen Intern Med (2010) 1.08
Multivariate Failure Times Regression with a Continuous Auxiliary Covariate. J Multivar Anal (2010) 1.07
Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail (2012) 1.07
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet (2008) 4.37
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32
Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27
Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res (2006) 3.80
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64
Assessment of blinding in clinical trials. Control Clin Trials (2004) 3.62
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J (2008) 3.52
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J (2008) 3.38
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22
Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. Circulation (2008) 3.19
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ (2005) 3.09
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (2003) 3.09
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J (2002) 3.05
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89
Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation (2010) 2.88
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension (2006) 2.83
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med (2011) 2.80